TA1
peptide · evidence: clinical · v1.0.0
Description
Thymosin alpha-1, discussed for immune modulation.
Mechanism summary
Potential T-cell and immune signaling modulation.
Reference details
Route(s): subcutaneous
Tags: immune, infection_support
Active: yes
Dosing references (verbatim from source — not recommendations)
1.5 mg SC twice weekly, or 450-900 mcg daily
twice weekly, or daily · 4-12 weeks · Repeat course per provider direction · subcutaneous
Source: Practitioner Peptide Dosing Reference (commonly published ranges) — Compiled practitioner reference (internal_protocol) · not yet provider-reviewed
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.